chufangao/CTO huggingface dataset:
Clinical trial NCT04176185: A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber
Official title: A Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) Sublingual Immunotherapy (SLIT)-Tablet in Adult Chinese Subjects With HDM Allergic Rhinitis/Rhinoconjunctivitis Using an Environmental Exposure Chamber
Acronym: QUEST
Sponsor: ALK-Abelló A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: COVID-19
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-04
Primary completion date: 2019-12-17
Completion date: 2022-01-19
Plan to share individual participant data: NO
Clinical trial NCT03871855: A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
Official title: A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor R \& D Strategy Adjustment
Enrollment: 8.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-04-28
Primary completion date: 2021-06-21
Completion date: 2021-06-21
Clinical trial NCT04349176: Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units?
Official title: OnabotulinumtoxinA for Chronic Headaches: Is 155 Units Superior to 100 Units?
Sponsor: United States Naval Medical Center, San Diego (FED)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Insufficient Recruitment
Enrollment: 35.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-05-12
Primary completion date: 2019-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT05221385: Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
Official title: A Phase Ia, Open-label, Dose Escalation Study of Safety, Tolerability, Pharmacokinetics of Gentulizumab, an Anti-CD47 Monoclonal Antibody, in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma (NHL)
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to changes in the sponsor's research strategy
Enrollment: 58.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-12
Primary completion date: 2023-05-30
Completion date: 2023-10-27
Plan to share individual participant data: NO
Clinical trial NCT03269344: Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
Official title: Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma
Sponsor: Henry Ford Health System (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 65.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-05
Primary completion date: 2020-12-09
Completion date: 2020-12-09
Plan to share individual participant data: NO
Clinical trial NCT02836340: TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA
Official title: TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest
Acronym: TIBOHCA
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Inclusion of patients slow
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-05-31
Primary completion date: 2019-12-31
Completion date: 2020-04-30
Plan to share individual participant data: NO
Clinical trial NCT05149287: PROPER Trial of Pain and Inflammation After Knee Arthroscopy
Official title: Early Reduction of Post-opeRative Pain and Inflammation to Expedite Return to Function After KNEE Arthroscopy
Acronym: PROPER
Sponsor: University of Kentucky (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funding stopped
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-28
Primary completion date: 2022-04-29
Completion date: 2022-04-29
Plan to share individual participant data: YES
IPD sharing description: With the participant's approval and as approved by local Institutional Review Boards (IRBs), de-identified biological samples will be stored at the University of Kentucky Orthopedic Biomarker Repository. These samples could be used to research the causes of osteoarthritis after cartilage or meniscus injury, its complications and other conditions for which individuals with cartilage or meniscus injuries are at increased risk, and to improve treatment.~Before sharing biomarker samples, we will ensure that the participant has given previous consent to the sharing of the information or samples. When we confirm that the previously provided consent is still in effect we will remove identifiers such as (e.g., name, medical record number, or date of birth). We will use a secure electronic log to track information shared without releasing the individual participant's identity.
IPD time frame: Access to individual participant data will be available 1 year after the final study follow-up has been completed, and will be available until 5 years after the final study follow-up has been completed.
IPD access criteria: The researchers requesting access to participant information or samples must complete a questionnaire describing why they need information or samples for their research and how they will use the information or samples. The researchers who receive the information or samples will sign an agreement to use the data responsibly.
Clinical trial NCT05312008: Does Oxytocin Alter Tolerance to or Motivation for Alcohol
Official title: Does Oxytocin Alter Tolerance to Alcohol or Motivation for Alcohol in Heavy Drinking Human Subjects: Testing a Novel Anti-Addiction Mechanism
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to complications delaying the availability of the intranasal oxytocin and IV alcohol solutions needed for this project, we were unable to complete subjects in the self-administration arm of this study.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-16
Primary completion date: 2023-12-21
Completion date: 2023-12-21
Plan to share individual participant data: YES
IPD sharing description: The final raw dataset will be available to other researchers when we have collected all subjects, completed our own planned analyses, and, if warranted, sought and obtained funding based on the outcome of this pilot study.
IPD time frame: The dataset will be available indefinitely
IPD access criteria: On request to the PI
Clinical trial NCT03619213: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Official title: An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Acronym: DELIVER
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 6263.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-27
Primary completion date: 2022-03-27
Completion date: 2022-03-27
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Clinical trial NCT03520985: Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma
Official title: Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Acronym: OptiPOM
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Feasibility (low patient accrual and financial reasons)
Enrollment: 34.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-01
Primary completion date: 2021-02-03
Completion date: 2021-02-03
Clinical trial NCT04481412: Topical Cetirizine in Androgenetic Alopecia in Females
Official title: The Role of Cetirizine in Androgenetic Alopecia in Females
Sponsor: Cairo University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 66.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-25
Primary completion date: 2021-11-30
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT02959359: DAA in the Risk of Recurrence After Curative Treatment of HCC
Official title: The Role of DAA in Reducing the Risk of Recurrence After Curative Treatment of HCC in Patients With Chronic Hepatitis C and Early Stage HCC
Sponsor: Taipei Veterans General Hospital, Taiwan (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The supplies of study drug were halted by Gilead Sciences Ltd.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-11-30
Primary completion date: 2022-06-30
Completion date: 2022-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04585724: Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Official title: Evaluation of Radiosurgery With Concurrent Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Brain Metastases
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Closed due to low (0) accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-12
Primary completion date: 2021-09-13
Completion date: 2021-09-13
Clinical trial NCT03430791: Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Official title: A Phase I/II Trial of Combination Tumor Treating Fields, Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Sponsor: Baptist Health South Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study Investigator/Sponsor decided to end enrollment earlier.
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-05
Primary completion date: 2020-05-29
Completion date: 2021-01-27
Baseline population: No participants with prior PD1/PDL1 checkpoint inhibitor were enrolled, thus no participants were assigned to the Nivolumab+Ipilimumab arm.
Limitations and caveats: Did not accrue the target number of participants needed to achieve target power and statistically reliable results.
Plan to share individual participant data: NO
Clinical trial NCT03925155: RCT Investigating Pre-cesarean Vaginal Wash of Chlorhexidine vs Povidone-iodine for Patient With Ruptured Amniotic Membrane.
Official title: A Randomized Trial to Investigate if a Pre-operative Wash With Chlorhexidine vs Povidone-iodine Vaginal Scrub Decreases Infectious Morbidity in Patients Undergoing Cesarean Section After Ruptured Membranes
Acronym: VAP
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The study was withdrawn from the IRB
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-01
Primary completion date: 2022-05-01
Completion date: 2023-05-01
Plan to share individual participant data: NO
Clinical trial NCT04698525: Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.
Official title: Efficacy of Memantine Compared With Sodium Valproate in the Prophylactic Treatment of Episodic Migraine.
Sponsor: Universidad Autonoma de San Luis Potosí (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-15
Primary completion date: 2020-01-15
Completion date: 2020-01-15
Baseline population: A total of 33 subjects participated in the trial, 6 of which left due to covid-19 infections. In the end, 27 subjects completed the trial.
Plan to share individual participant data: YES
IPD sharing description: This clinical trial is the thesis to obtain a specialist degree (Neurologist) of Dr. Damaris Daniela Vazquez-Guevara; at the end of the study, the plan is to publish as soon as possible.
IPD time frame: 12 months
IPD access criteria: 6 months
Clinical trial NCT05352542: GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Official title: A Phase I Clinical Trial for Evaluating the Safety, Tolerance and Efficacy of GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: achieve the proof of concept
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-05-19
Primary completion date: 2024-07-31
Completion date: 2024-07-31
Plan to share individual participant data: NO
Clinical trial NCT04033367: SAR231893-LPS15497- Dupilumab Effect on Sleep in AD Patients
Official title: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 188.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-22
Primary completion date: 2021-10-06
Completion date: 2021-10-06
Baseline population: Analysis was performed on intent-to-treat (ITT) analysis set which included all randomized participants with a treatment kit number allocated and recorded in the interactive response technology (IRT) database, regardless of whether the treatment kit was used or not and were analyzed according to the treatment group allocated by randomization.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT05013229: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Official title: A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL Combined With Insulin Aspart, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin. COMBINE 3
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 679.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-30
Primary completion date: 2023-11-14
Completion date: 2023-11-14
Clinical trial NCT03361956: An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection
Official title: A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection
Sponsor: Janssen Sciences Ireland UC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 232.0 (ACTUAL)
Number of arms: 10.0
Start date: 2018-02-13
Primary completion date: 2019-09-05
Completion date: 2020-08-13
Clinical trial NCT05563610: Oral Penicillin Challenge and Allergy De-labeling in Children
Official title: Oral Penicillin Challenge and Allergy De-labeling in the Phoenix Children's Hospital Emergency Department
Sponsor: Phoenix Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Unable to recruit sufficient number of subjects in the setting
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-26
Primary completion date: 2024-06-12
Completion date: 2024-06-12
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share IPD with other researchers at this time.
Clinical trial NCT05095961: Pre-operative Steroids in CRSsP
Official title: Effect of Pre-operative Oral Steroids on Blood Loss in Endoscopic Sinus Surgery for Chronic Rhinosinusitis Without Polyps
Sponsor: Loma Linda University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Technical difficulties encountered with recording intraoperative blood loss; unable to proceed with study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-03-31
Primary completion date: 2024-03-31
Completion date: 2024-08-31
Plan to share individual participant data: NO
Clinical trial NCT02920892: AFQ056 for Language Learning in Children With FXS
Official title: Effects of AFQ056 on Language Learning in Young Children With Fragile X Syndrome (FXS)
Acronym: FX-LEARN
Sponsor: Rush University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 110.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-08-17
Primary completion date: 2022-05-17
Completion date: 2022-05-17
Clinical trial NCT03085485: The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor
Official title: A Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Topic Trial)
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-16
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT02850419: Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients
Official title: Heat-Activated Target Therapy (Radiotherapy + Hyperthermia + Lyso-Thermosensitive Liposomal Doxorubicin) of Local-Regional Relapse in Breast Cancer Patients
Acronym: EURO-DIGNITY
Sponsor: Imunon (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Administrative
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-03-31
Primary completion date: 2019-12-31
Completion date: 2020-02-29
Clinical trial NCT02524119: LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
Official title: A Phase Ib/II Study of LEE011 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
Acronym: LEE001
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This study was terminated after the sponsor withdrew our support
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-04-30
Primary completion date: 2020-09-30
Completion date: 2020-09-30
Limitations and caveats: Data were not collected for some outcome due to early study termination.
Plan to share individual participant data: NO
Clinical trial NCT01912625: Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Official title: A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Inadequate accrual rate
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-10-28
Primary completion date: 2017-11-03
Completion date: 2023-02-24
Clinical trial NCT05099640: A Study of PTC923 in Participants With Phenylketonuria
Official title: A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Sponsor: PTC Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 157.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-09-30
Primary completion date: 2023-04-03
Completion date: 2023-05-03
Baseline population: Safety analysis set included all participants who received at least 1 dose of study drug, including during Part 1. Part 2 included participants (≥2 years of age) who experienced a ≥15% reduction in blood Phe levels (responder). Non-responders in Part 1 did not continue to Part 2.
Clinical trial NCT03894345: Prazosin Use in Adults With Anxiety Disorders
Official title: Open Label 8-Week Study of Prazosin Use in Adults With Anxiety Disorders
Sponsor: University of Manitoba (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: COVID-19
Enrollment: 20.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2019-05-24
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT03642145: A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)
Official title: A 52-Week Phase 3B Randomized Open-Label Study Evaluating the Safety and Pharmacokinetics of Emflaza® (Deflazacort) Compared to a Comparable Natural History Control Group in Males Aged ≥2 to <5 Years With Duchenne Muscular Dystrophy (DMD) Followed by a 52-Week Extension Period
Acronym: PTCEMF
Sponsor: PTC Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Study is no longer necessary given the safety and efficacy of emflaza in this age range has already been established after review of already available data.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-31
Primary completion date: 2021-07-31
Completion date: 2021-07-31
Clinical trial NCT03342950: The Effects of Topical Treatment With Clonidine + Pentoxifylline in Patients With Neuropathic Pain
Official title: The Effects of Topical Treatment With Clonidine + Pentoxifylline in Patients With Neuropathic Pain
Acronym: TTNP
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low recruitment due to the COVID-19 pandemic
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-19
Primary completion date: 2021-10-12
Completion date: 2021-10-12
Plan to share individual participant data: NO